Literature DB >> 12828606

Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.

Ming Yang1, Takuya Moriya, Mitsue Oguma, Clarissa De La Cruz, Mareyuki Endoh, Takanori Ishida, Hisashi Hirakawa, Yojiro Orita, Noriaki Ohuchi, Hironobu Sasano.   

Abstract

Microinvasive ductal carcinoma of the breast, namely ductal carcinoma in situ with microinvasion (T1mic) as defined by the American Joint Committee on Cancer (AJCC) Staging Manual, is a rare disease, although it is increasing because of widespread use of mammography. The aim of the present study was to describe the clinicopathological and immunohistochemical features of this entity. Twenty-eight patients who were diagnosed as T1mic from January 1997 to August 2002 were studied by using 3-5 mm-thick serial sections with hematoxylin-eosin staining. Immunohistochemical staining for the estrogen receptor (ER), progesterone receptor (PR), p53, Ki-67, and HER-2 were performed. All 28 patients were female, with a mean age of 48.8 years. Twenty-six patients (93%) revealed mammographic abnormalities on routine examination. All foci of the invasions were measured using an ocular micrometer. Invasive foci consisted of isolated cells or cell clusters, or appeared as a tongue-like projection of tumor through the basement membrane of the duct of ductal carcinoma in situ (DCIS). The mean number of invasive foci was 3, and the mean size was 0.6 mm. We found that high nuclear grade and predominant comedo subtype of DCIS components were 57.1% and 46.4%, respectively. Twenty-four cases (86%) demonstrated necrosis of DCIS components. Microinvasion was often associated with periductal stromal reaction (71.5%) and/or a lymphocytic infiltration (78.6%). All patients, excluding two, received axillary resection (the mean number of lymph nodes examined per case was 12), and none had lymph node metastasis. The positive expression of ER and PR strongly related to low grade nuclei and non-comedo subtype; however, the positive expression of HER-2 and P53 related to high grade nuclei and comedo subtype (P<0.01). Ki-67 expression was significantly higher in the high grade nuclei group than in the low grade group (P<0.01). Our study suggested that high nuclear grade and comedo DCIS were more aggressive and more common with microinvasion, and that microinvasion is more likely to be multifocal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828606     DOI: 10.1046/j.1440-1827.2003.01498.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  9 in total

1.  Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases.

Authors:  Pratima Nangia-Makker; Tirza Raz; Larry Tait; Malathy P V Shekhar; Hong Li; Vitaly Balan; Hemanckur Makker; Rafael Fridman; Krishnarao Maddipati; Avraham Raz
Journal:  Cancer Biol Ther       Date:  2013-02-04       Impact factor: 4.742

2.  Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death.

Authors:  Malathy P V Shekhar; Larry Tait; Robert J Pauley; Gen Sheng Wu; Steven J Santner; Pratima Nangia-Makker; Varun Shekhar; Hind Nassar; Daniel W Visscher; Gloria H Heppner; Fred R Miller
Journal:  Cancer Biol Ther       Date:  2008-11-12       Impact factor: 4.742

Review 3.  Microinvasive carcinoma of the breast.

Authors:  Simonetta Bianchi; Vania Vezzosi
Journal:  Pathol Oncol Res       Date:  2008-05-21       Impact factor: 3.201

4.  Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.

Authors:  Mieke Van Bockstal; Kathleen Lambein; Hannelore Denys; Geert Braems; Ann Nuyts; Rudy Van den Broecke; Veronique Cocquyt; Olivier De Wever; Louis Libbrecht
Journal:  Virchows Arch       Date:  2014-06-29       Impact factor: 4.064

5.  The Demographic Features, Clinicopathological Characteristics and Cancer-specific Outcomes for Patients with Microinvasive Breast Cancer: A SEER Database Analysis.

Authors:  Wenna Wang; Wenjie Zhu; Feng Du; Yang Luo; Binghe Xu
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

6.  Clinical and imaging characteristics of breast ductal carcinoma in situ with microinvasion.

Authors:  Sijia Han; Fang Qiu; Ye Han; Yongqing Xu; Jianqiao Yin; Fei Xing; Xiaobo Bian; Guijin He
Journal:  J Appl Clin Med Phys       Date:  2020-12-17       Impact factor: 2.102

7.  Proposal for Creating a Guideline for Cancer Registration of Microinvasive Tumors of the Breast and Ovary (II).

Authors:  Jin Hee Sohn; Gyungyub Gong; Kyu Rae Kim; Chang Suk Kang; Youn Soo Lee; Jin Man Kim; Woo Hee Jung; Kwang Sun Suh
Journal:  Korean J Pathol       Date:  2012-06-22

8.  Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery?

Authors:  Hai-Fei Niu; Li-Juan Wei; Jin-Pu Yu; Zhen Lian; Jing Zhao; Zi-Zheng Wu; Jun-Tian Liu
Journal:  Cancer Biol Med       Date:  2016-03       Impact factor: 4.248

9.  Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.

Authors:  Marie Beguinot; Marie-Melanie Dauplat; Fabrice Kwiatkowski; Guillaume Lebouedec; Lucie Tixier; Christophe Pomel; Frederique Penault-Llorca; Nina Radosevic-Robin
Journal:  BMC Cancer       Date:  2018-02-03       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.